Posted on 03/07/2021 8:49:45 PM PST by SeekAndFind
India’s ambitious but troubled campaign to inoculate its vast population against Covid-19 — and, in the process, to burnish its reputation as a manufacturer and innovator — received a major lift after initial trial results showed a homegrown vaccine was safe and effective.
Bharat Biotech, the Indian drug company that developed the shots, said late Wednesday that early findings from clinical trials involving nearly 26,000 subjects showed that the vaccine, Covaxin, had an initial efficacy rate of 81 percent.
The results have yet to be peer reviewed, the company said, and it was unclear how effective Covaxin would prove to be in a final analysis.
Still, the results were met with relief in India. Covaxin was approved by government officials in January and administered to millions of people even though it had not yet been publicly proved. Many in the country, including frontline health care workers, had feared that Covaxin could be ineffective or worse, slowing down the national campaign to inoculate 1.3 billion people.
Officials in Brazil, where the government had bought doses of Covaxin, had recently questioned whether the vaccine worked.
(Excerpt) Read more at nytimes.com ...
FROM YAHOO NEWS:
https://news.yahoo.com/covaxin-covishield-know-indias-covid-074404737.html
India’s Covaxin, the homegrown government-backed vaccine, has an efficacy rate of 81%, preliminary data from its phase 3 trial shows.
India’s regulators gave the vaccine an emergency approval in January while the third phase of the trial was still under way, sparking scepticism and questions from experts.
Bharat Biotech, the vaccine’s manufacturer, said the latest findings were “an important milestone in vaccine discovery, for science and our fight against coronavirus”.
“With today’s results from our phase 3 clinical trials, we have now reported data on our Covid-19 vaccine from phase 1, 2, and 3 trials involving around 27,000 participants,” the firm said.
[SNIP]
Bharat Biotech, a 24-year-old vaccine maker, has a portfolio of 16 vaccines and it exports to 123 countries.
Covaxin is an inactivated vaccine which means that it is made up of killed coronaviruses, making it safe to be injected into the body. Bharat Biotech used a sample of the coronavirus, isolated by India’s National Institute of Virology.
When administered, immune cells can still recognise the dead virus, prompting the immune system to make antibodies against the pandemic virus.
The two doses are given four weeks apart. The vaccine can be stored at 2C to 8C.
Bharat Biotech says it has a stockpile of 20 million doses of Covaxin, and is aiming to make 700 million doses out of its four facilities in two cities by the end of the year.
Wait....no mNRA agents?
This sounds good. A true vaccine, with a good efficacy rate? No fetal cells used in development and testing either?
RE: Wait....no mNRA agents?
NO. India’s is the traditional vaccine - an inactivated virus that allows the body to recognize a foreign invader and produce antibodies to it. Inactivated virus do not replicate ( considered DEAD ) but are still able to instruct the human immune system to mount a defensive reaction to an infection.
India’s Prime Minister Modi already took the injection on March 1 and urged others to follow suit.
Indeed!
Good for India. If they like their vaccine they can keep their vaccine. 😎
There is an American company that has acquired the licensing rights for this vaccine in the USA. Unfortunately it seems that they will be too late for the US market if they even get approval.
India’s infection rate is less than 1/10 of ours (and far lower recently) and their death rate is even better than that. And all due to Ivermectin. Hopefully they stick with that also.
Disclaimer: Opinions posted on Free Republic are those of the individual posters and do not necessarily represent the opinion of Free Republic or its management. All materials posted herein are protected by copyright law and the exemption for fair use of copyrighted works.